RPGLIFE

- Q2FY26 Quarterly Result Announced for RPG Life Sciences Ltd.

Pharmaceuticals company RPG Life Sciences announced Q2FY26 results Revenue from Operations: Rs 181.7 crore compared to Rs 168.9 crore during Q1FY26, change 7.6%. EBITDA: Rs 43.6 crore compared to Rs 40.7 crore during Q1FY26, change 7.1%. EBITDA Margin: 24.0% for Q2FY26. PBT: Rs 38.2 crore compared to Rs 35.4 crore during Q1FY26, change 7.9%. PAT: Rs 28.5 crore compared to Rs 26.3 crore during Q1FY26, change 8.1%. PAT Margin: 15.7% for Q2FY26. Results are better than expected. Thank you, Technofunda24 All this is for information. This is not a buy/sell recommendation. Sunil Kotak (Founder of SHUBH CONSULTANCY - SEBI Registered Research Analyst| INH000015826) Disclaimer: Investments are subject to market risk please read relevant documents before investing. Past performance will not guarantee the future results. My self/may associates do not own any stock discussed here. Me/My associates/My relatives do not have any conflict of Interest in the discussed stock. Me/My associates/My relatives have not received any compensation from the Company in last 12 months. Me/My associates/My relatives do not have holding above 1% in the stock discussed. This is for Intended Recipient only. Advisable to assume that we have recommended this one to our clients.